Inducible Resistance to Amikacin in Mycobacterium abscessus Isolated in Beijing, China

Inducible Resistance to Amikacin in Mycobacterium abscessus Isolated in Beijing, China

Zhijian Zhang,1,&ast; Wei Wang,2,&ast; Yufeng Wang,3 Zhongtan Xue,3 Shanshan Li,2 Yu Pang2 1Department of Respiratory and Critical Care Medicine, the Second Medical Center of Chinese PLA General Hospital, Beijing, 100036, People’s Republic of China; 2Department of Bacteriology and Immunology...

Full description

Bibliographic Details
Main Authors:	Zhang Z, Wang W, Wang Y, Xue Z, Li S, Pang Y
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-04-01
Series:	Infection and Drug Resistance
Subjects:	amikacin intrinsic resistance inducible mycobacterium abscesses
Online Access:	https://www.dovepress.com/inducible-resistance-to-amikacin-in-mycobacterium-abscessus-isolated-i-peer-reviewed-fulltext-article-IDR

Similar Items

Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence
by: Joy E. Gibson, et al.
Published: (2024-02-01)

Rapid Detection of Clarithromycin and Amikacin Resistance in Mycobacterium abscessus Complex by High-Resolution Melting Curve Analysis
by: Haoran Li, et al.
Published: (2022-06-01)

Analysis of Phenotypic and Genotypic Susceptibility to Clarithromycin and Amikacin of <i>Mycobacterium abscessus</i> Complex Strains Isolated from Cystic Fibrosis Patients
by: Juan Carlos Cao Yao, et al.
Published: (2023-11-01)

Mixed Infection of Mycobacterium abscessus subsp. abscessus and Mycobacterium tuberculosis in the Lung
by: Sungmin Sohn, et al.
Published: (2017-02-01)

Treatment Outcome in Patients with <i>Mycobacterium abscessus</i> Complex Lung Disease: The Impact of Tigecycline and Amikacin
by: Jeng-How Yang, et al.
Published: (2022-04-01)

Therapeutic drug monitoring in peritoneal dialysis: A case of nontuberculous mycobacterium catheter‐related infection treated with amikacin
by: Sanae Kojya, et al.
Published: (2020-06-01)

Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory <i>Mycobacterium avium</i> Complex Pulmonary Disease
by: Bo-Guen Kim, et al.
Published: (2020-09-01)

Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China
by: Md Mahmudul Islam, et al.
Published: (2020-09-01)

Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues
by: Styliani Xiroudaki, et al.
Published: (2021-01-01)

Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use
by: Seong Min Kim, et al.
Published: (2023-06-01)

Clinical Pharmacokinetics of Amikacin in Neonates
by: Gian Maria Pacifici, et al.
Published: (2017-02-01)

Mycobacterium abscessus urinary tract infection in an immunocompetent host: A case report and literature review
by: Abdulrahman F. Al-Mashdali, et al.
Published: (2022-01-01)

Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia
by: Sameh Seyam, et al.
Published: (2022-06-01)

Intrathecal use of amikacin: a case report
by: L. Barrou, et al.

The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
by: Khan O, et al.
Published: (2020-06-01)

Molecular drug susceptibility testing against the first-line (rifampin and isoniazid) and second-line (ciprofloxacin–amikacin and kanamycin) treatment in different subtypes of Mycobacterium simiae
by: Parissa Farnia, et al.
Published: (2016-01-01)

Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches
by: Thanh Quang Nguyen, et al.
Published: (2024-02-01)

Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings
by: Morita A, et al.
Published: (2022-07-01)

Heteroresistance to Amikacin in Carbapenem-Resistant Klebsiella pneumoniae Strains
by: Feiyang Zhang, et al.
Published: (2021-12-01)

Amikacin: Uses, Resistance, and Prospects for Inhibition
by: Maria S. Ramirez, et al.
Published: (2017-12-01)

Designing and comparison study of rapid detection methods of resistance to injectable drugs in clinical strains of Mycobacterium tuberculosis
by: Fatemeh Salehi, et al.
Published: (2012-01-01)

Tigecycline-amikacin combination effectively suppresses the selection of resistance in clinical isolates of KPC-producing Klebsiella pneumoniae
by: Wentao Ni, et al.
Published: (2016-08-01)

Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report
by: Hashimoto K, et al.
Published: (2023-10-01)

Protective effect of creatine on amikacin-induced ototoxicity
by: Emre Apaydın, et al.
Published: (2022-09-01)

Successful Treatment of Serious Meningitis Caused by Extremely Carbapenem-Resistant Enterobacter cloacae (MIC≥16mg/L) with i.v. Meropenem and i.v. Amikacin Plus Intraventricular Amikacin
by: He Z, et al.
Published: (2019-12-01)

Antibiotic resistance in Mycobacterium Abscessus and Mycobacterium Fortuitum isolates from Malaysian patients
by: Sharmilla Devi Jayasingam, et al.
Published: (2017-01-01)

Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis
by: Molinaro M, et al.
Published: (2018-09-01)

Arabinosyltransferase C Mediates Multiple Drugs Intrinsic Resistance by Altering Cell Envelope Permeability in Mycobacterium abscessus
by: Shuai Wang, et al.
Published: (2022-08-01)

The Direction of the Antibacterial Effect of Rutin Hydrate and Amikacin
by: Maria Miklasińska-Majdanik, et al.
Published: (2023-09-01)

Effect of mannitol on the pharmacokinetics of amikacin in wistar rats
by: Hugo Juárez Olguín, et al.
Published: (2009-08-01)

Intraperitoneal Amikacine Provoked Perceptive Deafness in CAPD - Continuous Ambulatory Peritoneal Dialysis Patient
by: Lutfi Zylbeari, et al.
Published: (2020-07-01)

Review on Population Pharmacokinetics of Amikacin in Paediatrics
by: Keerthana Chandrasekar, et al.
Published: (2022-12-01)

A Diet with Amikacin Changes the Bacteriobiome and the Physiological State of <i>Galleria mellonella</i> and Causes Its Resistance to <i>Bacillus thuringiensis</i>
by: Olga V. Polenogova, et al.
Published: (2023-11-01)

The Involvement of Drug Efflux System in Amikacin Resistance of Multiple Drug Resistant Acintobacter baumannii Isolates in Isfahan, Iran
by: Yalda Ostadi, et al.
Published: (2019-02-01)

The Role of Aspirin as Otoprotective Agent in Patients Receiving Amikacin Therapy
by: Estabraq M. Mahdi
Published: (2011-06-01)

Standard Multiple and Single Daily Dosing of Amikacin in Premature Infants
by: Arash Bordbar, et al.
Published: (2017-12-01)

A Comparison of Antimicrobial Resistance of XDR and MDR clinical isolates of E. coli, Klebsiella spp. & Pseudomonas spp. against Amikacin & Imipenem
by: Zuhair Ali Rizvi, et al.
Published: (2019-12-01)

Mycobacterium abscessus Complex Infections in Humans
by: Meng-Rui Lee, et al.
Published: (2015-09-01)

Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus
by: Shelby Daniel-Wayman, et al.
Published: (2019-05-01)

Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors
by: Lauma Freimane, et al.
Published: (2023-03-01)